Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galson Backed Initial Plan B Denial In Fear His Job Was In Jeopardy – Jenkins

Executive Summary

Center for Drug Evaluation & Research Director Steven Galson initially signed off on the "not approvable" letter for Barr's emergency contraceptive Plan B OTC switch in fear that he would lose his job, according to testimony by senior CDER officials

You may also be interested in...



Plan B Decision May Offer FDA Best Political Protection Available

Assuming that sexually charged products such as Teva’s emergency contraceptive remain subject to political decision-making, the explicit heavy hand of the HHS secretary in the OTC switch ruling may be the best approach for FDA and the Rx industry, especially considering the alternatives.

FDA’s Florence Houn Joins Celgene Regulatory Affairs Department

Celgene has tapped FDA's Florence Houn as VP-regulatory policy and strategy at a time when the company is working to comply with the Risk Evaluation and Mitigation Strategies provisions of the FDA Amendments Act

FDA’s Florence Houn Joins Celgene Regulatory Affairs Department

Celgene has tapped FDA's Florence Houn as VP-regulatory policy and strategy at a time when the company is working to comply with the Risk Evaluation and Mitigation Strategies provisions of the FDA Amendments Act

Related Content

UsernamePublicRestriction

Register

PS047532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel